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Abstract
Background: Dramatic weight loss is an often underestimated symptom in pancreatic cancer patients. Cachexia-
defined as an unintended loss of stable weight exceeding 10% – is present in up to 80% of patients with cancer of the
upper gastrointestinal tract, and has a significant influence on survival. The aim of the study was to show the multiple
systemic effects of cachexia in pancreatic cancer patients, in terms of resection rate, effects on pulmonary function,
amount of fat and muscle tissue, as well as changes in laboratory parameters.
Methods: In patients with pancreatic cancer, clinical appearance was documented, including the amount of weight loss.
Laboratory parameters and lung-function tests were evaluated, and the thickness of muscle and fat tissue was measured
with computed tomography scans. Statistical analysis, including multivariate analysis, was performed using SPSS software.
Survival curves were calculated using Kaplan-Meier analysis and the log-rank test. To test for significant differences
between the examined groups we used Student's t-test and the Mann-Whitney U test. Significance was defined as p <
0.05.
Results: Of 198 patients with a ductal adenocarcinoma of the pancreas, 70% were suffering from weight loss when they
presented for operation, and in 40% weight loss exceeded 10% of the stable weight. In patients with cachexia, metastases
were diagnosed significantly more often (47% vs. 24%, P < 0.001), leading to a significantly reduced resection rate in these
patients. Patients with cachexia had significantly reduced fat tissue amounts. Hence, dramatic weight loss in a patient with
pancreatic cancer may be a hint of a more progressed or more aggressive tumour.
Conclusion: Pancreatic cancer patients with cachexia had a higher rate of more progressed tumour stages and a worse
nutritional status. Furthermore, patients with cachexia had an impaired lung function and a reduction in fat tissue. Patients
with pancreatic cancer and cachexia had significantly reduced survival. If weight loss exceeded 5% there was a significantly
reduced resection rate to detect, but the changes were significantly more substantial if weight loss was 10% or more.
We propose that a weight loss of 10% be defined as significant in pancreatic cancer.
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Pancreatic cancer is the fourth leading cause of cancer-
related deaths in Western countries [1,2]. In 2006, an esti-
mated 32,000 deaths were related to pancreatic cancer in
the United States (U.S.) [3]. More than 90% of pancreatic
cancers are ductal adenocarcinomas, which often present
with perineural and retroperitoneal infiltration. An early
diagnosis is necessary, and after the exclusion of meta-
static disease, surgical resection of the tumour is the
patient's only hope for cure [1,4-10]. Resection offers a
significantly improved prognosis, with a median survival
of 14–20 months and up to 25% 5-year survival rates.
However, most patients have advanced disease at the time
of presentation, with various signs and symptoms, such as
bile duct obstruction, abdominal pain, loss of appetite, or
vomiting [11].
A dramatic weight loss, with subsequent complications, is
an often-underestimated symptom, present in two-thirds
of the patients with malignant tumors [11-14]. Cancer
patients who have lost weight have a poorer prognosis
than patients with stable weight [14,15]. A recent study
with patients suffering from pancreatic cancer demon-
strated, that weight stabilisation was associated with
longer survival [16].
The loss of muscle and fat- tissue is mediated by different
alterations in the organism, not all of which are known
until now [17]. In recent years there has been a major
effort to identify the mechanisms underlying muscle and
fat degradation in cancer cachexia. One important mech-
anism is the activation of the acute phase response cas-
cade, resulting in loss of fat and muscle tissue. In patients
with pancreatic cancer and an activated acute phase
response cascade, weight loss is accelerated, leading to sig-
nificantly shorter survival [18,19]. Both, increased mus-
cle-protein degradation and reduced muscle-synthesis
result in a net loss of muscle tissue [17,20]. Subsequently,
pancreatic cancer patients often have an elevated resting
energy expenditure (REE) [21]. Additionally, the oral food
intake in these patients is lower. This results in a lean body
mass depletion. For muscle degradation, the ubiquitin-
proteasome pathway is the most important mechanism
[22]. Agustsson and coworkers found that in patients with
cancer cachexia, adipocyte lipolysis is activated by a hor-
mone-sensitive lipase [23].
Cachexia, defined as an unintended weight loss of 10% or
more of the stable weight over a period of 6 months, is
present in up to 80% of patients with cancer of the upper
gastrointestinal tract [24-26]. A cachectic status has an
influence on survival, 30- day- mortality and morbidity
[12].
Up to 80% of patients with cancer of the gastrointestinal
tract suffer from dyspnea [27,28]. Frequency and severity
of dyspnea increase with the progression of the disease
[27]. In patients with impaired lung function preopera-
tively (vital capacity less than 50% of the normal level or
less than 2 litres), about every fifth patient can be expected
to have pulmonary insufficiency postoperatively [29].
Another important parameter of the pulmonary function
is the forced expiratory volume in one second; healthy
individuals have values over 70% of the vital capacity
measured, compared to patients with cancer of the gas-
trointestinal tract [29].
The aim of this study was to investigate the influence of
cachexia on early changes in patients with pancreatic can-
cer, with a special interest in the systemic effects of
cachexia on fat and muscle tissue and on lung function.
Methods
Patients
In 198 patients with histologically confirmed adenocarci-
noma of the pancreas, who underwent operation in the
Department of Surgery, University of Heidelberg, between
June 2004 and February 2006, a careful history was taken
and lung function tests were performed. Table 1 shows the
patients' characteristics in detail. The study was performed
according to the guidelines of the Declaration of Helsinki,
and each patient was asked to give written informed con-
sent for data collection as well as for publication of data
in an anonymous manner. All data and examinations in
this study were acquired in clinical routine, therefore an
ethical approval was not needed. All data were collected in
a prospectively designed database.
Weight and body composition
For every patient the current height and weight were regis-
tered; when a patient was suffering from weight loss, the
time period was also documented. A patient was classified
as cachectic, when he had lost 10% or more of his stable
pre-illness weight.
Histological diagnosis
For each patient two independent pathologists form the
Department of Pathology, University of Heidelberg, con-
firmed the diagnosis. Resected tumours were classified
histopathologically according to the TNM classification,
version 2005, including examination of the resection mar-
gin and grading. Tumour staging was determined accord-
ing to the UICC classification 2006 [30,31].
Morbidity
Every complication which prolonged the hospital stay
and/or had to be treated (by interventional placing of a
drain, reoperation, or non-invasive therapy) was noted.
The prevalence of wound infection, postoperative bleed-Page 2 of 9
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N = 119 [60.1%]
with cachexia
N = 79 [39.9%]
p value
gender male 67 [56.3] 49 [62] P = 0.425
female 52 [43.7] 30 [38]
ASA classification I 2 [1.7] 1 [1.3] P = 0.023
II 57 [47.9] 26 [32.9]
III 60 [50.4] 50 [63.3]
IV 0 [0] 2 [2.5]
resection rate 95 [79.8] 38 [48.1] P < 0.001
metastases 29 [24.4] 37 [46.8] P < 0.001
tumour stage UICC II 83 [69.7] 37 [46.8] P < 0.001
UICC III 7 [5.9] 5 [6.3]
UICC IV 29 [24.4] 37 [46.8]
30-day mortality 4 [3.4] 4 [5.1] P = 0.561
morbidity 50 [42.0] 36 [46.2] P = 0.568
albumin [g/l] 44.2 [41.1/46.1] 41.45 [39.5/43.8] P < 0.001
CA19-9 [U/l] 165.0 [41.3/579.0] 308.0 [43.7/1454.0] P = 0.163
CrP [mg/l] 5.0 [1.0/11.3] 9.4 [3.0/32.8] P = 0.002
haemoglobin [g/dl] 13.3 [12.15/14.35] 12.8 [11.8/13.7] P = 0.023




N = 95 [71.4%]
with cachexia
N = 38 [28.6%]
P value
ASA classification I 2 [2.1] 0 [0] P = 0.363
II 48 [50.5] 17 [44.7]
III 2 [47.4] 21 [55.3]
30-day mortality 2 [2.1] 1 [2.6] P = 0.854
morbidity 43 [45.3] 36 [46.2] P = 0.144
albumin [g/l] 44.1 [40.9/45.9] 41.6 [39.5/43.9] P = 0.010
CA19-9 [U/l] 151.0 [34.0/416.0] 203.6 [25.25/721.0] P = 0.657
CrP [mg/l] 5.1 [1.0/11.8] 6.6 [2.2/16.2] P = 0.282
haemoglobin [g/dl] 13.1 [12.05/14.25] 13.1 [12/13.7] P = 0.349
protein [g/l] 73.8 [71.1/77.2] 70.75 [68.6/75.25] P = 0.053
Tumor size T3 92 [96.8] 38 [100] P = 0.270
T4 3 [3.2] 0 [0]
grade G1 4 [4.3] 4 [11.1] P = 0.166
G2 57 [61.3] 23 [63.9]
G3 32 [34.4] 9 [25.0]
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abscesses, delayed gastric emptying, pneumonia, urinary
tract infection, myocardial infarction, and pulmonary
embolism were evaluated [32,33].
Pulmonary function tests
Lung function was measured using a spirometer (OPTI
PLEX 466le). A standardised protocol was used, and
before the test began the procedure was demonstrated to
the patient by an independent examiner, who did not
know whether the patient had cachexia. In every patient
the vital capacity (VC) in absolute and relative values of
the expected values as well as forced expiratory volume in
one second (FEV1) was documented.
Measurement of fat and muscle tissue on computed 
tomography scans
Every patient received a contrast-enhanced CT scan. A
venous phase of a computed tomography scan of the
abdomen was chosen.
Six different values were taken: (figure 1 shows an exam-
ple of the measured lengths) the thickness of the perirenal
fat [1] and of thesubcutaneous fat [4] and [5]; Thickness
of muscle was measured in two different locations–the
musculus erector spinae [2] and the musculus psoas [3a]–
and area was measured as well [3a].
Statistical analysis
Statistical analysis, including multivariate analysis, was
performed using SPSS software, version 16 (SPSS Inc.,
Chicago, IL, U.S.). Survival curves were calculated using
Kaplan-Meier analysis and the log-rank test. To test signif-
icant differences between the examined groups, we used
Student's t-test and the Mann-Whitney U test. Significance
was defined as p < 0.05. Results are reported as median
and lower (lq) and upper (uq) quartiles.
Results
Of 198 patients (116 men and 82 women; median age 64
[57/79] years) with a histologically proven adenocarci-
noma of the pancreas, 69.7% (138) patients presented
with weight loss; in 39.9% (79) of the patients, weight
loss exceeded 10% of the pre-illness stable weight (table
1), and these patients were therefore categorized as
cachectic. In patients without cachexia, the median time
period, in which weight loss occurred was 2 [1/4] [lower
quartile/upper quartile] months; in patients with cachexia
it was 4 [2/6] months (P < 0.001).
In 67.2% (133) of patients a tumour resection could be
performed; in the other 32.8% (65) a palliative operation
(either an explorative laparotomy or a bypass operation)
was performed due to locally advanced tumour growth or
distant metastases to the peritoneal cavity or the liver.
Table 1 shows the patient characteristics in the patients
scheduled for tumour resection; they were divided into a
group with and a group without cachexia (table 1).
The resection rate was significantly lower in patients with
cachexia (P < 0.001). In 79.8% of patients without
cachexia a tumour resection was performed, whereas a
resection was only possible in 48.1% of patients with
cachexia. Patients with cachexia had significantly pro-
gressed tumour stages (P < 0.001, table 1): 24.4% of
patients without cachexia had occult distant metastases
diagnosed on explorative laparotomy; in contrast, metas-
tases to the peritoneal cavity or the liver were present in
46.8% of patients with cachexia (P < 0.001). There were
A: CT slide of renal pelvisFigure 1
A: CT slide of renal pelvis. [1] perirenal fat: ortho-
graphic to renal capsule and to line 2. [2] musculus erector 
spinae: thickness of the muscle in a parallel line to the dorsal 
process Figure 1B: CT slide of iliac crest. [3a] thickness of 
the musculus psoas in a parallel line to the dorsal process. 
[3b] area of the psoas muscle. [4] subcutaneous fat 
medial: parallel to the dorsal process. [5] subcutaneous 
fat lateral: parallel to the dorsal process starting at iliac 
spine posterior superior area of the psoas muscle.
A
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groups in 30-day mortality (P = 0.561) and perioperative
morbidity (P = 0.568), even when corrected for tumour
resection and palliative operation. In this series perioper-
ative course was no worse in patients with cachexia than
in those without cachexia.
Blood tests showed significant differences in protein levels
(P = 0.037) and albumin levels (P < 0.001), with signifi-
cantly lower levels in patients with cachexia compared to
patients without cachexia, demonstrating a worse nutri-
tional status in cachectic patients. Haemoglobin values
were also significantly reduced in patients with cachexia
(P = 0.023), without any signs or symptoms of occult
bleeding. CA19-9 values, as markers for tumour load,
were not significantly different between patients with and
without cachexia (P = 0.163), demonstrating that it is not
tumour load that is essential but the aggressiveness of
tumour biology, represented by the systemic alterations in
patients with cachexia. The values for C-reactive protein
were significantly elevated in patients with cachexia (P =
0.002). In patients in whom a tumour resection could be
performed, there was no significant difference in tumour
size (P = 0.270, table 1) or grade (P = 0.166) between
patients with and without cachexia.
To illustrate the impact of cachexia on pulmonary func-
tion, lung function tests were performed in patients with
and without cachexia. In the 150 examined patients there
was a significantly worse vital capacity (vc%) in patients
with cachexia (P = 0.032); in absolute values there was no
significant difference (P = 0.142, table 2). The forced end
expiratory volume was not significantly different between
the two groups (P = 0.514) as well as in relative values (P
= 0.137).
In 175 of the patients the thickness of perirenal fat could
be assessed with a CT scan. We found no significant differ-
ence in perirenal fat thickness between patients with
cachexia and without cachexia (table 4). In the lower part
of the abdomen, on the iliac crest slides, there was no sig-
nificant difference between the two groups in any of the
examined muscle tissue thicknesses. In contrast, fat tissue
thickness levels were significantly reduced in patients with
cachexia: subcutaneous fat medial (P = 0.016) and lateral
(P = 0.007) (Figure 1, table 2).
Patients with cachexia had significantly worse survival
than patients without cachexia (figure 2, P = 0.042).
When all patients with non-metastasised tumours were
compared, patients with cachexia again had shorter sur-
vival (P = 0.067), but in UICC stage IV this difference
became significant (P = 0.008). In multivariate analysis,
tumour stage (P < 0.001) and weight loss (P = 0.003) sig-
nificantly influenced survival.
To demonstrate that a weight loss of 10% has a significant
influence in patients with pancreatic cancer, the evalua-
tion was also performed using a weight loss of 5% as a
division parameter. With this separation there was also a
significantly worse resection rate in patients suffering
from weight loss of 5% or more (P < 0.001), with metas-
tases detected significantly more often on explorative
laparotomy in patients with weight loss exceeding 5% (P
= 0.006) than in patients with weight loss of less than 5%.
Accordingly, in patients with weight loss of 5% or more,
the tumour stages were significantly worse (P = 0.011).
In the examined lab work no significant difference could
be detected between patients with weight loss of less or
more than 5% (table 5). Furthermore, with this separa-
tion there was no significant difference in lung function
tests, amount of perirenal fat, or muscle thickness (table
3).
Table 2: lung function tests (N = 150) and amount of perirenal fat (N = 175), muscle (N = 123) and subcutaneous fat (N = 123) Median 






VC [l] 3.3 [2.7/3.9] 3.1 [2.4/3.9] P = 0.142
VC [%] 93.0 [80.0/102.0] 84.5 [75.0/97.5] P = 0.032
FEV 1 [l] 2.8 [2.5/3.5] 2.7 [2.3/3.4] P = 0.514
FEV 1 [%] 100 [88.0/115.0] 98.0 [82.0/108.0] P = 0.137
perirenal fat [1] 9.0 [5.1/13.5] 8.3 [5.1/11.2] P = 0.336
M. erector spinae [2] 33.0 [29.2/36.5] 31.5 [26.9/36.3] P = 0.343
M. psoas [3a] 45.1 [38.1/113.0] 49.3 [40.2/130.1] P = 0.126
M. psoas area [3b] 1158.3 [854.5/1487.3] 1228.9 [952.7/1484.8] P = 0.713
subcut. fat medial [4] 14.4 [7.5/22.8] 7.9 [5.5/16.9] P = 0.016
subcut. fat lateral [5] 44.5 [35.1/56.3] 38.0 [27.0/45.9] P = 0.007Page 5 of 9
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better survival when a curative resection could be per-
formed (UICC II, P < 0.001). When metastases were
detected on explorative laparotomy there was no signifi-
cant difference in survival between patients with and
without cachexia. In patients with cachexia survival was
reduced even after curative resection (P = 0.067); survival
was dramatically reduced in cachectic patients who had
undergone palliative operations (P = 0.008).
Even after curative resection, survival was significantly
reduced in patients suffering from weight loss of 5% or
more (P < 0.001) in comparison to patients with less than
5% weight loss. In contrast, when metastases to the liver
or peritoneal cavity were detected, the division parameter
of 5% did not show any significant difference. However,
when weight loss exceeded 10% in patients with metas-
tases, survival was significantly reduced.
Discussion
In this study of 198 patients with a ductal adenocarci-
noma of the pancreas we assessed the prevalence of
cachexia and its systemic effects. To show an influence of
cachectic status on lung function tests and muscle and fat
tissue in patients before pancreatic surgery, corresponding
data were acquired in selected areas using CT scans. Fur-
thermore, we studied the influence of a dramatic weight
loss on postoperative survival.
This study found that 70% of the patients who presented
for pancreatic cancer resection were suffering from weight
loss, and that in 40% of these patients this loss of weight
exceeded 10% of their stable pre-illness weight. These
findings demonstrate that even in selected patients who
are scheduled for pancreatic cancer resection, nearly 40%
present with a significant preoperative weight loss and
only 30% do not suffer from weight loss at the time of
tumour resection. In 67% of all patients, a tumour resec-
tion could be performed: the resection rate in patients
with cachexia was significantly worse, due to more fre-
quent diagnosis of metastases to the liver and/or perito-
neal cavity. A dramatic weight loss in a patient with
pancreatic cancer can be a hint of a more progressed and
aggressive tumour.
CA 19-9 is used as a tumour marker in pancreatic cancer.
In a study of 176 patients resected for pancreatic cancer,
the level of CA19-9 correlated with tumour size[34,35] In
Kaplan-Meier survival curve in 198 patients with pancreatic cancer with and without cachexia (p < 0.001) showing a significant longer survival in patients without cach xiaFigure 2
Kaplan-Meier survival curve in 198 patients with pancreatic cancer with and without cachexia (p < 0.001) 
showing a significant longer survival in patients without cachexia.Page 6 of 9
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19-9 levels between patients with and without cachexia,
which indicates similar tumour sizes in these patients; the
more often progressed tumour stage in patients with
cachexia thus suggests a more aggressive tumour rather
than a larger tumour of the pancreas. These findings are
underlined by the fact that no significant differences in
tumour size could be seen in patients with and without
cachexia after tumour resection. Also with regard to
tumour grade, no significant difference between patients
with and without cachexia could be detected. This shows
that cachexia is not correlated with tumour mass or grade
in resectable pancreatic cancer.
Albumin, protein and haemoglobin are serum markers
which show the nutritional status in patients with cancer
[36]. All three of these markers were significantly reduced
in pancreatic cancer patients with cachexia, indicating a
worse nutritional status. Despite this worse nutritional
status, no significant influence on perioperative morbid-
ity and 30-day mortality was detected in this series. The
morbidity and 30-day mortality rates in our patients are
consistent with rates in other publications [37].
The cachectic syndrome had a significant impact on the
lung function tests in pancreatic cancer patients with
cachexia; the relative vital capacity was significantly worse
in these patients; despite this finding, the impaired lung
function test results had no negative influence on periop-
erative mortality and morbidity. There was no significant
difference between the two groups in the examined mus-
cle thicknesses; despite this finding, the lung function in
pancreatic cancer patients with cachexia was significantly
reduced, showing that in the early stages of the cachectic
syndrome the muscle is preserved, but the function of the
muscle is impaired. We could demonstrate a significant
influence of cachexia on fat metabolism, leading to signif-
icantly reduced fat tissue amounts in pancreatic cancer
patients with cachexia; this result underlines the systemic
effects of cachexia in patients with pancreatic cancer.
In patients with cachexia the survival was shortened even
after curative resection, but survival was dramatically
reduced in patients with cachexia undergoing palliative
operations.
In the literature there is often a weight loss of 5% or 10%
chosen to define cachexia. Therefore we chose 5% and
10% to demonstrate the changes in results, when weight
loss is 10% or more. In patients suffering from weight loss
exceeding 5% there is already a significant reduced resec-
tion rate to detect, but there are not yet differences seen in
laboratory parameters and lung function. But when
weight loss is 10% or more, there are many more signifi-
cant changes seen: first of all a significant reduced resec-
tion rate is obvious, as there are significantly more often
Table 3: P values for differences in the parameters weight loss </> 5% and, </> 10% respectively
parameter Weight loss </> 5% Weight loss </> 10%
ASA classification P = 0.017 ▼ P = 0.023 ▼
resection rate P < 0.001 ▼ P < 0.001 ▼
metastases P = 0.006 ▼ P < 0.001 ▼
tumour stage P = 0.011 ▼ P < 0.001 ▼
30-day mortality P = 0.925 ▬ P = 0.561 ▬
morbidity P = 0.988 ▬ P = 0.568 ▬
albumin P = 0.054 ▬ P < 0.001 ▼
CA19-9 P = 0.383 ▬ P = 0.163 ▬
CrP P = 0.116 ▬ P = 0.002 ▼
haemoglobin P = 0.595 ▬ P = 0.023 ▼
protein P = 0.089 ▬ P = 0.037 ▼
VC [l] P = 0.283 ▬ P = 0.142 ▬
VC [%] P = 0.161 ▬ P = 0.032 ▼
FEV 1 [l] P = 0.118 ▬ P = 0.514 ▬
FEV 1 [%] P = 0.731 ▬ P = 0.137 ▬
perirenal fat [1] P = 0.955 ▬ P = 0.336 ▬
M. erector spinae [2] P = 0.790 ▬ P = 0.343 ▬
M. psoas [3a] P = 0.449 ▬ P = 0.126 ▬
M. psoas area [3b] P = 0.243 ▬ P = 0.713 ▬
subcut. fat medial [4] P = 0.004 ▼ P = 0.016 ▼
subcut. fat lateral [5] P = 0.063 ▬ P = 0.007 ▼Page 7 of 9
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changes in laboratory results, amount of fat and muscle
tissue and lung function to detect. These findings confirm
the fact that a weight loss of 10% has a more significant
systemic effect in patients with pancreatic cancer and not
5% but 10% should be chosen as the divison parameter.
But nevertheless, the symptom "weight loss" in a patient
with pancreatic cancer should make one think of more
progressed disease.
The multivariate analysis performed revealed tumour
stage and weight loss as significant factors influencing sur-
vival in patients with pancreatic cancer.
Conclusion
In conclusion, we showed that nearly 40% of patients
with pancreatic cancer who present for tumour resection
suffer from weight loss of 10% or more of their stable pre-
illness weight. Due to metastases to the liver and/or peri-
toneal cavity, the resection rate is significantly reduced in
patients with cachexia. A dramatic weight loss in a patient
with pancreatic cancer may hint at a more progressed or
more aggressive tumour.
A weight loss of 10% had a significant systemic effect,
which was not as strong as for a 5% weight loss; the resec-
tion rate was also significantly worse when weight loss
exceeded 5%, but the nutritional status showed significant
differences only when the division parameter was weight
loss of 10%.
The most obvious systemic effect of cachexia in pancreatic
cancer are the following: 1) a higher rate of more pro-
gressed tumour stages in patients with cachexia, 2) a
worse nutritional status, indicated by lower protein, albu-
min, and haemoglobin levels, 3) impaired lung function,
and 4) the reduction of fat tissue. Overall, patients with
cachexia and pancreatic cancer had significantly reduced
survival, and in patients undergoing curative resection
even a weight loss of 5% showed significant differences.
After detection of metastases, only a preoperative weight
loss of 10% worsened survival.
As weight loss of 10% in patients with pancreatic cancer
produces more dramatic effects and changes in preopera-
tive laboratory results and the postoperative course, this
should be the essential division parameter in pancreatic
cancer patients.
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